FDA slams repackager for unsupported drug expiration dates

A Massachusetts drug repackager has been cited by the FDA for failing to provide cleaning protocols for equipment that is used for packaging multiple products. (Lohxa)

The FDA has slapped around a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations. 

The warning letter for Worcester, Massachusetts-based Lohxa criticized the plant for giving lots of repackaged unit dose drugs, including pneumonia treatment atovaquone oral suspension, expiration dates of 12 months from repackaging but had no data to support the dates. 

The company claimed to have data to support a six-month expiration date, but the FDA said it never made the information available.

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

The inspection of the plant occurred earlier in the year but was only recently posted. 

RELATED: API repackager in hot water with FDA

On the cleaning front, the Lohxa plant had no data to back up its equipment cleaning processes. The FDA pointed out that one machine is used to fill different drugs into unit dose containers, including the highly potent API atropine, but could not provide protocols to show the equipment was cleaned thoroughly enough to prevent cross-contamination. 

Finally, the inspector found no indication that the plant had carefully investigated consumer complaints about leaking cups to find a cause. The agency says managers couldn’t even show how the complaint was received. 

The FDA wants Lohxa to upgrade all of those processes and resolve the issues ASAP. 

These kinds of issues with a repackager are not new. In 2017, an FDA warning letter was issued for the Decatur, Alabama, plant of API repackager Apothecares. In that case, the facility was cited for extending the expiration dates on a number of drugs without the plant’s quality unit signing off on the change.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.